In vitro-in vivo correlation: Application in pharmaceutical development of various dosages forms

Journal of Chemical and Pharmaceutical Research

Volumn 3, Issue 5, 2011, Pages 550-564

  Nandy, Bankim C ^a   Roy, Sandipan ^b   Mazumder, Bhaskar ^c   Meena, Kailash C ^a   Ahuja, Dharmedra ^a   Makhija, Manju ^a   Jain, Swati ^a   Sharma, Stuti ^a   Shrivastava, Arti ^a   Saxena, Priya ^a  

^a Jayoti Vidyapeeth Women's University   (India)

^b DR REDDY'S LABORATORIES LTD   (India)

^c DIBRUGARH UNIVERSITY   (India)

Author keywords

Bcs; Convolution; Correlation; Deconvolution; Dissolution

Indexed keywords

CONTROLLED RELEASE FORMULATION; CORRELATION ANALYSIS; DISSOLUTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG DOSAGE FORM; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG RELEASE; IN VITRO IN VIVO CORRELATION; IN VITRO STUDY; IN VIVO STUDY; MATHEMATICAL MODEL; PREDICTION; REVIEW;

EID: 80053496805     PISSN: None     EISSN: 09757384     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. U.S. Department of Health and Human Services. Guidance for industrial. Extended release oral dosage forms: Development, evaluation and application of In vitro/In vivo correlations. Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Rockville, MD, 1997.
2. J Skelly; G Amidon; W Barr; L Benet; F Carter; J Robinson; V Shah; A Yacobi. Pharm.Res., 1990, 7,975-982.
3. In vitro and In vivo Evaluation of Dosage Forms. In USP 26-NF 21; United States Pharmacopeial Convention, Inc.: Rockville, MD, 2002, 1088.
4. In vitro Release Testing and In vivo Bioequivalence Documentation; Guidance for Industry; U.S. Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (CDER),U.S. Government Printing Office: Washington, DC, 1997.
5. Note for Guidance on Development Pharmaceutics; European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit, Committee for Proprietary Medicinal Products, CPMP/QWP/155/96, London, U.K., 1998.
6. Note for Guidance on Modified Release Oral and Transdermal Dosage Forms: Section II (Pharmacokinetic and Clinical Evaluation); European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit, Committee for Proprietary Medicinal Products, CPMP/EWP/280/96, London, U.K., 1999.
7. M Silverman; SV Burgen. J. Appl. Physiol.,1961,16, 911-913.
8. A Rescigno; G Segre. Drug and Tracer Kinetics, Blaisdell Publishing Co, Waltham, MA, 1966, 75.
9. M Hanano. Chem. Pharm. Bull.,1967, 15, 994-1001.
10. D.P. Vaughan, M. Dennis, Mathematical basis of point-area de-convolution method for determining in vivo input functions, J. Pharm. Sci. 67 (1978) 663-665.
11. D.J. Cutler, Numerical de-convolution by least squares: use of prescribed input functions, J. Pharmacokin. Biopharm. 6 (1978) 227-241.
12. D. J. Cutler, Use of polynomials to represent the input function, Ibid 6(1978) 243-263.
13. D. J Cutler. J. Pharmacokin. Biopharm., 1978, 6, 265-282.
14. D. J Cutler. Pharmacol. Ther., 1981, 14,123-160.
15. P. Veng-Pedersen. J. Pharm. Sci., 1980, 69, 298-305.
16. P. Veng-Pedersen. Ibid,1980, 69, 305-312.
17. P. Veng-Pedersen. J. Pharm. Sci., 1980, 69, 312-318.
18. P Veng-Pedersen. J. Pharmacokin. Biopharm., 1980, 8, 463-481.
19. F. Langenbucher. Pharm. Ind., 1982, 44,1166-1172.
20. F. Langenbucher. Pharm. Ind., 1982, 44, 1275-1278.
21. F. Langenbucher; H Moeller. Pharm. Ind., 1983, 45,623-628.
22. F. Langenbucher; H Moeller. Ibid, 1983,45,629-633.
23. F. Langenbucher; J Mysicka. Br. J. Clin. Pharmacol.,1985, 19,51S-162S.
24. V. F Smolen; WA Weigand. J. Pharm. Sci., 1976, 65,1718-1724.
25. V. F Smolen. J. Pharmakin. Biopharm., 1976, 4, 337-353.
26. V. F Smolen. Ibid, 1976, 4, 355-375.
27. V. F Smolen; RJ Erb. J. Pharm. Sci., 1977, 66, 287-304.
28. V. F Smolen. Practical pharmacodynamic engineering in the design, development and evaluation of optimal drug products, in: HS Bean; AH Beckett; JE Carless. Advances in Pharmaceutical Sciences, 1982, Academic Press, London, 145-161.
29. USP23/NF18, k1088l. In vitro and in vivo evaluations of dosage forms, 1995, 924-929.
30. FDA. Guidance for Industry: extended release oral dosage forms: development, evaluation and application of in vitro/in vivo correlations, Diss. Technol., 1997, 23-32.
31. J. Gabrielsson; D Weiner. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications, Swed. Pharm. Press, Stockholm, Sweden, 1997, 275-291.
32. D. Young; J. G Devane; J Butler. In vitro-In vivo Correlations, Plenum Press, New York, 1997, 53-56.
33. S. Blanquet; E. Zeijdner; E. Beyssac; J. P. Meunier; S. Denis; R. Havenaar; M. Alric. Pharm. Res., 2004, 21, 37-49.
34. MN Martinez; GL Amidon. J. Clin. Pharmacol., 2002, 42, 620-643.
35. E Mathiowitz. Encyclopaedia of Controlled Drug Delivery. John Wiley & Sons., 1999, 1, 425-434.
36. J Dressman; J Krammer. Pharmaceutical Dissolution Testing. Taylor & Francis Group., 2005, 1-34.
37. G L Mattok; R D Hossie; I J McGilveray. Can. J. Pharm. Sci., 1972, 7, 84.
38. TRD Shaw; K Raymond; M R Howard; J Hamer. Br. Med. J.,1973, 4, 763.
39. LF Chasseaud; T Taylor; RM Major; IW Taylor; V Luckow; A Darragh; RF Lambe. Arzneim- Forsch., 1983, 33(2), 1298-1301.
40. GL Amidon; H Lennernäs; VP Shah; JR Crison. Pharm. Res., 1995, 12, 413-420.
41. JB Dressman; D Fleisher. J. Pharm. Sci., 1986.75, 109-116.
42. C Mircioiu; I Mircioiu; V Voicu; D Miron. Basic Clin. Pharmacol. Toxicol., 2005, 96 (3),262-264.
43. J. E. Polli; J. R. Crison; G. L. Amidon. J. Pharm. Sci., 1996, 85 (7),753-760.
44. S Hayes; A Dunne; T Smart; J Davis. J.Pharm. Sci., 2004, 93 (3), 571-581.
45. P Macheras; A Iliadis. Modeling in biopharmaceutics, pharmacokinetics and pharmacodynamics: homogeneous and heterogeneous approaches, Springer, New York, 2006, 200-206.
46. JC Boylan; J Swarbrick. Encyclopedia of Pharmaceutical Technology, vol I, 2nd ed. Marcel Dekker, New York,2002, pp 811-852.
47. B. J. West; W. Deering. Phys. Rep., 1994, 246, 1-100.
48. L Ritger; N. A. Peppas. J. Control. Release, 1987, 23-37.
49. R Kopelman. Science, 1988, 241, 1620-1626.
50. K Kosmidis; P Macheras. Int. J. Pharmaceut., 2007, 343, 166-172.
51. K Kosmidis; P Argyrakis; P Macheras. Pharm. Res., 2003,20.
52. K Kosmidis; P Argyrakis; P Macheras. J. Chem. Phys., 2003, 119, 6373-6377.
53. A Bunde; S Havlin; R Nossal; HE Stanley; GH Weiss. J. Chem. Phys., 1985, 83 5909-5913.
54. A Barat; HJ Ruskin; M Crane. Simul. Model. Pract.,2006, 14,843-856.
55. A Barat; HJ Ruskin; M Crane. Simul. Model. Pract., 2006,14,857-873.
56. R Villalobos; AM Vidales; S Cordero; D Quintanar; A Domnguez. J. Sol-Gel Sci. Technol., 2006, 37, 195-199.
57. R Villalobos; A Ganem; S Cordero; AM Vidales; A Domnguez. Drug Dev. Ind. Pharm., 2005, 31, 535-543.
58. N Haddish-Berhane; C Nyquist; K Haghighi; C Corvalan; A Keshavarzian; O Campanella; J Rickus; A Farhadi. J. Control.Release, 2006, 110,314-322.
59. V. Papadopoulou; K Kosmidis; M Vlachou; P Macheras. Int. J. Pharm., 2006, 309, 44-50.
60. I. M Sokolov; J Klafter; A Blumen. Phys. Today, 2002, 55 (11) 48-55.
61. W Weitschies; RS Wedemeyer; O Kosch; K Fach; S Nagel; E Söderlind; L Trahms; B Abrahamsson; H Mönnikes. J. Control. Release, 2005, 108 (2-3), 375-385.
62. PH Marathe; EP Sandefer; GE Kollia; DS Greene; RH Barbhaiya; RA Lipper; RC Page; WJ Doll; UY Ryo; GA Digenis. J. Pharmacokinet. Biopharm., 1998, 26 (1), 1-20.
63. ZS Wang; Z He; JD Chen. IEEE Trans. Biomed. Eng., 2004, 51 (8), 1401-1406.
64. GA Kossena; WN Charman; CG Wilson, B O Mahony; B. Lindsay; J.M. Hempenstall; CL Davison; PJ Crowley; CJ Porter. Pharm. Res., 2007, 24 (11), 2084-2096.
65. JW Moore; H H Flanner. Pharm. Technol., 1996, 20, 64-74.
66. VP Shah; Y Tsong; P Sathe; RL Williams; Dissolution Technol., 1999, 6 (3), 15.
67. E Galia; E Nicolaides; D Hörter; R. Löbenberg; C. Reppas; J. B. Dressman. Pharm. Res., 1998, 15, 698-705.
68. P E Macheras; M Koupparis; E Apostolleli. Int. J. Pharm., 1987, 36, 125-136.
69. P Finholt; S Solvang; J. Pharm. Sci., 1968, 57, 1322-1326.
70. E Demrturk; L Öner. J. Pharm. Sci., 2003, 28, 215-224.
71. I Iran. J Pharm Pharmaceut Sci., 2006, 9 (2), 169-189.
72. B S Tanwer, R Choudhary, R Vijayvergia, J. Chem. Pharm. Res., 2010, 2(2): 489-495